You are here

Coronary Intervention & Surgery


A cross-sectional study of nearly 1,300 patients revealed Chinese physicians systematically overestimate the severity of coronary stenosis, perhaps even more so than in the United States, likely leading to many patients being inappropriately treated with percutaneous coronary intervention (PCI).

The risk of another heart attack following percutaneous coronary intervention (PCI) was twice as likely to originate from a previously untreated lesion versus the stented lesion, according to a study of a large Swedish cohort published in the Journal of the American Heart Association.

Patients are significantly more likely to die within one year of coronary artery bypass graft (CABG) surgery or PCI in New York state than in England where the procedures are roughly four times cheaper, according to a study in Open Heart.

Temporarily cooling part of the heart during myocardial infarction (MI) and again immediately after angioplasty may reduce damage to the heart, said a cardiologist who participated in the first in-human study of the technique.

Charles E. Chambers, MD, spoke with Cardiovascular Business about the risks of radiation exposure to interventional cardiologists and potential solutions.


Recent Headlines

ORBITA investigators publish response to critics

The two lead investigators of ORBITA have published a comprehensive response to criticisms of their provocative trial.

PCI outcomes similar at top-ranked, unranked hospitals

Hospitals ranked in the top 50 for cardiology and heart surgery by U.S. News and World Report appear no better at performing PCI than unranked hospitals, according to an analysis of more than 500,000 procedures performed at 654 hospitals.

Studies in JACC show progress for PCI of CTOs

PCI of chronic total occlusions (CTOs) can be safely performed by expert operators and provides significant benefit to patients with reduced left ventricular ejection fraction (LVEF) or diabetes, according to a series of studies published Nov. 13 in JACC: Cardiovascular Interventions.

Bioresorbable scaffold discontinuity a major mechanism of very late thrombosis

Scaffold discontinuity, malapposition and neoatherosclerosis were found to be the leading mechanisms behind very late scaffold thrombosis (VLScT) in cardiac patients implanted with bioresorbable devices, investigators from the INVEST registry have reported.

TCT 2017: Could doctors perform robot-assisted PCI over long distances?

Recent studies have shown robotic PCI to be a feasible way to treat coronary artery disease. But at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference Oct. 30, Ryan D. Madder, MD, took the conversation a step further: Will it eventually be possible to perform “tele-stenting” over long distances?

TCT 2017: PCI clinically superior, cost-effective versus medical therapy for patients with reduced FFR

Research presented Nov. 2 at the Transcatheter Cardiovascular Therapeutics scientific symposium in Denver demonstrates patients with stable coronary artery disease (CAD) and abnormal fractional flow reserve (FFR) derive better clinical outcomes with PCI at similar cost to medical therapy alone.

TCT 2017: Investigational device repairs mitral valves while heart beats

An image-guided cardiac device designed to repair the mitral valve while a patient’s heart is still beating could provide a safe, effective alternative to traditional open heart surgery, according to research presented Nov. 1 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Denver.

TCT 2017: Innovative trial suggests placebo effect plays role in symptomatic improvement from PCI

Differences in exercise duration for patients with stable angina who received either PCI or a placebo treatment were not statistically significant, according to research presented Nov. 2 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and published simultaneously in The Lancet.

TCT 2017: TMVR technique proves successful in 1st-ever trial

Transcatheter mitral valve replacement (TMVR) using a new self-expanding, tri-leaflet bovine valve was a success in the majority of patients enrolled in a pioneering global study, according to data presented this week at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in Denver.

TCT 2017: 1st 3-year results of ABSORB III trial a 'major damper' on bioresorbable scaffolds

The first three-year results of Abbott’s ABSORB III trial were announced at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) conference Oct. 31, nearly two months after Abbott Vascular withdrew its bioresorbable scaffold from the commercial market.